New drug targets tough cancers with KRAS mutation
Disease control
Ongoing
This early-stage study tests a new drug, HBI-2438, in people with advanced cancers (like lung, colon, or pancreatic) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves through the body. About 44 adult…
Phase: PHASE1 • Sponsor: HUYABIO International, LLC. • Aim: Disease control
Last updated Apr 29, 2026 01:50 UTC